Antiplatelet agents have a beneficial effect in reducing all cause mortality and fatal cardiovascular events in patients with IC .
BACKGROUND Peripheral arterial disease ( PAD ) is common and is a marker of systemic atherosclerosis .
Patients with symptoms of intermittent claudication ( IC ) are at increased risk of cardiovascular events ( myocardial infa rct ion ( MI ) and stroke ) and of both cardiovascular and all cause mortality .
OBJECTIVES To determine the effectiveness of antiplatelet agents in reducing mortality ( all cause and cardiovascular ) and cardiovascular events in patients with intermittent claudication .
Inhibition of spontaneous platelet aggregation and adhesion by indobufen (K 3920). A randomized, double-blind crossover study on platelet, coagulation and fibrinolysis function tests.
In a r and omized double-blind crossover study in 12 patients with atherosclerotic disease , the effect of 2 dosages ( 100 and 200 mg twice daily ) of indobufen , a new synthetic inhibition of platelet aggregation , on some platelet functions , coagulation and fibrinolysis tests was investigated . Regardless of the dosage used , indobufen was shown to induce a prompt normalization of the enhanced platelet aggregation of these patients . The effect lasted for the entire period of drug administration and in 50 % of patients a normal platelet aggregation was maintained until the fourth day after discontinuation of the drug . Indobufen was also able to reduce platelet adhesiveness and to lengthen bleeding time , especially when the higher dosage was used
Antiplatelet agents have a beneficial effect in reducing all cause mortality and fatal cardiovascular events in patients with IC .
BACKGROUND Peripheral arterial disease ( PAD ) is common and is a marker of systemic atherosclerosis .
Patients with symptoms of intermittent claudication ( IC ) are at increased risk of cardiovascular events ( myocardial infa rct ion ( MI ) and stroke ) and of both cardiovascular and all cause mortality .
OBJECTIVES To determine the effectiveness of antiplatelet agents in reducing mortality ( all cause and cardiovascular ) and cardiovascular events in patients with intermittent claudication .